Products HIL-214 + Placebo
HIL-214 + Placebo Phase 2/3 Terminated ⚡ Active Apr 28, 2022 → Sep 30, 2024
About HIL-214 + Placebo HIL-214 + Placebo is a phase 2/3 stage product being developed by HilleVax for Gastroenteritis. The current trial status is terminated. This product is registered under clinical trial identifier NCT05281094. Target conditions include Gastroenteritis.
Clinical Trials (2) NCT ID Phase Status Start Completion Indication NCT05836012 Phase 2/3 Completed Jun 10, 2023 Jul 8, 2024 Gastroenteritis NCT05281094 Phase 2/3 Terminated Apr 28, 2022 Sep 30, 2024 Gastroenteritis
Product Company Stage Hype Score Placebo + HIL-214 HilleVax Phase 1 HIL-214 + Placebo HilleVax Phase 2/3 HIL-214 HilleVax Phase 2 Benralizumab + Placebo AstraZeneca Phase 2/3 Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP) + Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP) Merck Phase 3 Rotavirus Vaccine Merck Pre-clinical Rotavirus Vaccine, Live, Oral, Pentavalent Merck Phase 3 RotaTeq (V260) + IPV Merck Phase 3 V260 + Placebo to V260 + OPV + DTaP Merck Phase 3 Prulifloxacin + Placebo Merck Phase 3 Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Placebo + Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Placebo Merck Phase 1 RotaTeq™ experimental formulation + RotaTeq™ existing formulation Merck Phase 3 prulifloxacin Merck Phase 3 montelukast Merck Pre-clinical Bacillus Clausii Sanofi Phase 3 Bacillus clausii + Oral Rehydration Therapy Sanofi Approved VXA-G1.1-NN (high dose) Oral Vaccine Tablet + VXA-G1.1-NN (low dose) Oral Vaccine Tablet Vaxart Phase 1 VXA-G1.1-NN Oral Vaccine Vaxart Phase 1 RHB-102 + Placebo Oral Tablet RedHill Biopharma Phase 3
Other Products from HilleVax